Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-005583-25
    Sponsor's Protocol Code Number:COLIMERO
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2014-07-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-005583-25
    A.3Full title of the trial
    Multicenter, randomized, open label, controlled clinical trial that compares the efficacy of the combination of colistin and meropenem versus monotherapy for the treatment of bacteremia and pneumonia due to Pseudomonas aeruginosa extremely resistant with reduced sensitivity to meropenem
    Ensayo clínico multicéntrico, aleatorizado, abierto y controlado, que compara la eficacia de la combinación de colistina y meropenem versus colistina en monoterapia para el tratamiento de bacteriemias y neumonías por Pseudomonas aeruginosa extremadamente resistente con sensibilidad reducida a meropenem.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Multicenter randomised clinical trial comparing the efficacy of the combination of colistin as monotherapy versus colistin plus meropenem for the treatment of bacteriemia and pneumonia due to extremely resistant.
    Ensayo clínico multicéntrico aleatorizado que compara la eficacia de la combinación de colistina y meropenem versus colistina en monoterapia para el tratamiento de bacterias y neumonías.
    A.4.1Sponsor's protocol code numberCOLIMERO
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorConsorci Parc de Salut Mar de Barcelona
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInsituto Carlos III (AES)
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationHospital del Mar
    B.5.2Functional name of contact pointServicio Enfermedades Infecciosas
    B.5.3 Address:
    B.5.3.1Street AddressPasseig Marítim, 25-29
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08003
    B.5.3.4CountrySpain
    B.5.4Telephone number0034932483251
    B.5.5Fax number0034932483257
    B.5.6E-mail97244@parcdesalutmar.cat
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Colistimetato de Sodio
    D.2.1.1.2Name of the Marketing Authorisation holderG.E.S; Genéricos ESpañoles Laboratorio, S.A.
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameColistimetato de sodio
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCOLISTIN
    D.3.9.1CAS number 1066-17-7
    D.3.9.4EV Substance CodeSUB01429MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number480
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Meropenem
    D.2.1.1.2Name of the Marketing Authorisation holderActavis Group PTC ehf.
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMeropenem
    D.3.2Product code Meropenem
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSM-7338
    D.3.9.1CAS number 96036-03-211
    D.3.9.2Current sponsor codeMeropenem
    D.3.9.3Other descriptive nameMEROPENEM ANHYDROUS
    D.3.9.4EV Substance CodeSUB49628
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Bacteriemia and Pneumonia due to Pseudomonas aeruginosa
    Bacteriemias y neumonías por Pseudomonas aeruginosa
    E.1.1.1Medical condition in easily understood language
    Bacteriemia and Pneumonia
    Bacteriemias y neumonías
    E.1.1.2Therapeutic area Diseases [C] - Bacterial Infections and Mycoses [C01]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the superiority in efficacy of intravenous colistin combination with intravenous meropenem treatment for pneumonia or bacteremia due to extremely resistant Pseudomonas aeruginosa with reduced sensitivity to meropenem, as measured by clinical and microbiological cure at 5-7 days after completion of therapy (test of cure).
    Demostrar la superioridad en cuanto a eficacia de la combinación de colistina intravenosa con meropenem intravenoso en el tratamiento dirigido de la bacteriemia o neumonía por Pseudomonas aeruginosa extremadamente resistente con sensibilidad reducida a meropenem, medida como curación clínica y microbiológica a los 5-7 días tras la finalización del tratamiento (test de curación).
    E.2.2Secondary objectives of the trial
    ? To compare mortality at 30 days and hospital stay
    ? To compare the incidence of toxicity ( safety ).
    ? Analyze the plasma levels of colistin, colistimethate sodium , meropenem and if , in the patients studied , at different times of the treatment cycle and correlate with clinical and microbiological response and toxicity.
    ? Study the MICs of colistin and meropenem in strains from patients. Relate these initial MICs with the final outcome ( clinical and microbiological cure and mortality ) .
    ? Analyze interactions in vitro of antibiotics used alone and in combination against isolates ( synergy test ) .
    ? Analyze the bactericidal power of the serum of the patients and correlate with clinical and microbiological response .
    ? Describe the molecular epidemiology and mechanisms of resistance of P. aeruginosa strains isolated from extremely resistant patients.
    ?Comparar la mortalidad a los 30 días y la estancia hospitalaria
    ?Comparar la incidencia de toxicidad (seguridad).
    ?Analizar los niveles plasmáticos de colistina, colistimetato sódico, y meropenem en su caso, en los pacientes estudiados, en diferentes momentos del ciclo de tratamiento y correlacionarlos con la respuesta clínica y microbiológica y con la toxicidad.
    ?Estudiar las CMIs de colistina y meropenem en las cepas provenientes de los pacientes. Relacionar estas CMIs iniciales con el pronóstico final (curación clínico-microbiológica y mortalidad).
    ?Analizar las interacciones in vitro de los antibióticos utilizados solos y en combinación frente a las cepas aisladas (tests de sinergia).
    ?Analizar el poder bactericida del suero de los pacientes incluidos y correlacionarlo con la respuesta clínica y microbiológica.
    ?Describir la epidemiología molecular y los mecanismos de resistencia de las cepas de P. aeruginosa extremadamente resistentes aisladas de los pacientes.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Both gender, aged 18 years old patients at time of the screening visit.
    2. Patients with bacteremia and /or pneumonia due to extremely resistant P. aeruginosa with reduced sensitivity to meropenem and colistin susceptible that require treatment with colistine at physician criterion. In the case of bacteremia it would be enough with one positive blood culture for that type of P. aeruginosa. Pneumonia is defined with the following diagnostic criteria:
    2.1 Acute onset of at least 3 of the following signs and symptoms (new or worsening)
    a. Cough.
    b . Purulent sputum.
    c . Dyspnea.
    d . Chest pain due to pneumonia.
    2.2 At least 1 of the following:
    a. Fever: defined as an axillary temperature superior or equal than 38 ° C
    b . Hypothermia is defined as an axillary temperature minor than 35 ° C
    c . Rales on lung auscultation and/or evidence of pulmonary consolidation (dullness to percussion , bronchial breath sounds or egophony) .
    2.3 Presence of parenchymal infiltrates lobar, multilobar or compatible with an acute bacterial pneumonia in a lung study (example: chest radiography preferably posteroanterior and lateral, one plane is acceptable if it is conclusive; or computed tomography of chest) in the 48 hours prior to first dose of study drug. The researcher can interpret the imaging study to decide whether the patient is suitable for inclusion.
    Patients with ventilator-associated pneumonia may also be included.
    3. Significant culture of respiratory samples will be considered as the presence of extremely resistant P. aeruginosa sputum culture of good quality (grade V: more than 25 polymorphonuclear leukocytes per field, and less than 10 epithelial cells or grade IV: over 25 polymorphonuclear leukocytes per field and 10-25 epithelial cells per field), or bronchial aspirate with more than 104 CFU/mL, or bronchoalveolar lavage with more than 103 CFU/mL or telescoping catheter culture with more than 103 CFU / mL. The presence of positive blood cultures for P. aeruginosa extremelyresistant in a patient with pneumonia it will be attributable to pneumonia in absence of other apparent source although cultures of respiratory samples are negative.
    4. Patients able to understand study implications and demonstrate thus signing the informed consent voluntarily. The unconscious patients may participate in the trial whenever a family member or legal representative sign the informed consent designed for this purpose.
    5. Patients of childbearing potential must have a negative pregnancy test.
    1. Pacientes de ambos sexos, mayores de 18 años de edad en el momento de la visita de selección.
    2. Pacientes con bacteriemia y/o neumonía por P. aeruginosa extremadamente resistente con sensibilidad reducida a meropenem y sensible a colistina, y que precisen tratamiento con colistina a criterio de su médico responsable. En el caso de bacteriemia bastaría con un solo hemocultivo positivo para dicho tipo de P. aeruginosa. Para las neumonías se considerarán los siguientes criterios diagnósticos:
    2.1.- Inicio agudo de al menos 3 de los siguientes signos y síntomas (aparición o empeoramiento):
    a. Tos.
    b. Producción de esputo purulento.
    c. Disnea.
    d. Dolor torácico debido a la neumonía.
    2.2-. Al menos 1 de los siguientes:
    a. Fiebre: definida como una temperatura axilar > 38 °C
    b. Hipotermia: definida como una temperatura axilar < 35 °C
    c. Estertores en la auscultación pulmonar y/o indicios de consolidación pulmonar (matidez a la percusión, ruidos respiratorios bronquiales o egofonía).
    2.3.- Presencia de infiltrados parenquimatosos lobulares, multilobulares o parcheados compatibles con una neumonía bacteriana aguda en un estudio de imágenes pulmonar (p. ej., radiografía de tórax [RxT] posteroanterior y lateral preferiblemente, un solo plano es aceptable si es concluyente] o tomografía computarizada [TC] de tórax) en las 48 horas anteriores a la primera dosis del fármaco del estudio. El investigador puede interpretar el estudio de imágenes para decidir si el paciente es apto para la inclusión. No obstante, también puede interpretarlo el radiólogo local.
    Los pacientes con neumonía asociada a ventilación mecánica también pueden incluirse. Ésta se define como el proceso neumónico que desarrollan los enfermos en ventilación mecánica entre las 48 horas de la intubación y las 48 horas de la retirada de la ventilación mecánica,
    sin evidencia clínica de neumonía antes de la intubación.
    3.- Se considerará cultivo significativo de muestras respiratorias la presencia de P. aeruginosa extremadamente resistente en un cultivo de esputo de buena calidad (grado V: más de 25 leucocitos polimorfonucleares por campo, y menos de 10 células epiteliales o grado IV: más de 25 leucocitos polimorfonucleares por campo y 10-25 células epiteliales por campo), o un broncoaspirado con más de 104 UFC/mL, o un lavado bronquioalveolar con más de 103 UFC/mL o un cultivo de catéter telescopado con con más de 103 UFC/mL. La presencia de hemocultivos positivos para P. aeruginosa extremadamente resistente en un paciente con neumonía se considerará atribuible a la neumonía en ausencia de otro foco aparente aunque los cultivos de las muestras respiratorias sean negativos. Si se aísla otro germen en las muestras respiratorias en cantidad significativa sería criterio de exclusión.
    4. Pacientes capaces de comprender las implicaciones del estudio y que así lo demuestren mediante su firma voluntaria del consentimiento informado. Los pacientes inconcientes podrán participar en el ensayo siempre que un familiar o representante legal firme el consentimiento informado diseñado a estos efectos.
    5.- Las pacientes potencialmente fértiles deberán tener un test de gestación negativo.
    E.4Principal exclusion criteria
    1. Allergy to penicillin or colistin, or hypersensitivity to the active principle or any of drug study.
    2. Epilepsy.
    3.Pregnant or breast feeding.
    4. Participation in any other clinical trial at 3 months prior to administration of the drug.
    5. Colonization without infection.
    6. Any other concomitant infection.
    7. Polymicrobial bacteremia.
    8. Las neumonías In: simultaneous cultivate for more germs.
    9.In neumony: other not infectious Causes of pulmonary infiltration (heart failure, pulmonary thromboembolism, active pulmonary cancer).
    9. Patient in terminal situation.
    10. Renal failure that requieres substitutive treatment.
    11. Antimicrobial active treatment active during more than 72 hours.
    12. Women in fertile age and sexually active not able to use anticonceptive methods.
    13. Any concomitant conditions that, in opinion of the investigator, could interfere at the study conduction.
    1. Alergia a la penicilina o a la colistina, o hipersensibilidad al principio activo o a alguno de los excipientes de la ficha técnica de los medicamentos del estudio.
    2. Epilepsia.
    3. Mujeres embarazadas o en periodo de lactancia.
    4. Participación en alguna investigación clínica dentro de los 3 meses anteriores a la administración del fármaco.
    5. Colonización sin infección.
    6. Otra infección concomitante.
    7. Bacteriemia polimicrobiana.
    8. En las neumonías: cultivo valorable para más gérmenes de forma simultánea.
    9.En las neumonías: otras causas no infecciosas de infiltrados pulmonares (insuficiencia cardíaca, tromboembolismo pulmonar, cáncer de pulmón activo).
    9. Paciente en situación terminal.
    10. Insuficiencia renal que precise tratamiento sustitutivo.
    11. Tratamiento antimicrobiano empírico plenamente activo durante más de 72 horas.
    12. Mujeres en edad fértil y vida sexual activa (se excluyen de esta definición mujeres cuya fecha de la última menstruación sea superior a un año a la inclusión en este estudio y aquellas a las que se les haya practicado una ligadura de trompas o una histerectomía), que no accedan a tomar medidas anticonceptivas aceptables durante el ensayo.
    13. Cualquier afección concomitante que, en opinión del investigador, pudiera impedir la evaluación de la respuesta o que hiciera improbable completar el ciclo previsto de tratamiento y seguimiento (p. ej., una esperanza de vida menor de 30 días).
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the rate of clinical and microbiological cure at 5-7 days after completion of therapy (test of cure ).

    Clinical cure it's defined as resolution of all symptoms of bacteremia and / or pneumonia who were present at the time of extraction of blood or respiratory cultures initial samples.
    Specifically bacteremia in clinical cure includes the resolution of fever (axillary temperature > 38 ° C ) if present, and the initial symptoms of the outbreak originating in bacteremia.
    In patients with clinical cure pneumonia include resolution of respiratory and systemic symptoms and the PaO2/FiO2 ratio is stable or has improved.

    Microbiological cure requires :
    - In the case of bacteremia the disappearance of the initial bacteremia , ie , negative blood culture 5 -7th days after the end of treatment ( or above ( at visit 2 or 3).
    - In the case of pneumonia if respiratory secretions cultures are negative in the test of cure. If the patient has secretions microbiological cure is assumed.
    Demostrar la superioridad en cuanto a eficacia de la combinación de colistina intravenosa con meropenem intravenoso en el tratamiento dirigido de la bacteriemia o neumonía por Pseudomonas aeruginosa extremadamente resistente con sensibilidad reducida a meropenem, medida como curación clínica y microbiológica a los 5-7 días tras la finalización del tratamiento (test de curación).

    Se define curación clínica como la resolución de todos los síntomas de bacteriemia y/o neumonía que estuvieran presentes en el momento de la extracción del hemocultivo o de los cultivos de muestras respiratorias iniciales.
    De forma específica en las bacteriemias la curación clínica incluye la resolución de la fiebre (temperatura axilar > 38ºC) si estaba presente, y de los síntomas iniciales del foco originario de la bacteriemia.
    En pacientes con neumonía la curación clínica incluye la resolución de los síntomas respiratorios y sistémicos y que la ratio PaO2/FiO2 esté estable o haya mejorado.
    La curación microbiológica exige:
    - En el caso de las bacteriemias la desaparición de la bacteriemia inicial, es decir, hemocultivo negativo al 5º-7º días tras la finalización del tratamiento (o antes si se han
    cursado por fiebre durante el tratamiento).
    - En el caso de las neumonías si los cultivos de secreciones respiratorias son negativos en el test de curación. Si el paciente no tiene secreciones se asumirá la curación microbiológica.
    E.5.1.1Timepoint(s) of evaluation of this end point
    At 5-7 days after completion of therapy (test of cure ).
    A los 5-7 días tras la finalización del tratamiento (test de curación).
    E.5.2Secondary end point(s)
    -To compare mortality at 30 days and hospital stay.
    -To compare the incidence of toxicity (safety).
    -Analyze the plasma levels of colistin, colistimethate sodium, meropenem and where appropriate, at different times of the treatment cycle and correlate with clinical and microbiological response and toxicity.
    -Study the MICs of colistin and meropenem in strains from patients. Relate these initial MICs with the final outcome (clinical and microbiological cure and mortality).
    -Analyze interactions in vitro of antibiotics used alone and in combination against isolates (synergy test).
    - Analyze the serum bactericidal and correlate with clinical and microbiological response.
    -Describe the molecular epidemiology and mechanisms of resistance of strains of P. aeruginosa isolated extremely resistant.
    - Adverse events during treatment (nefrotoxicity/neurotoxicity/diarrhoea per Clostridium difficile).
    -Comparar la mortalidad a los 30 días y la estancia hospitalaria.
    -Comparar la incidencia de toxicidad(seguridad ).
    -Analizar los niveles plasmáticos de colistina, colistimetato sódico, y meropenem en su caso, en diferentes momentos del ciclo de tratamiento y correlacionarlos con la respuesta clínica y microbiológica y con la toxicidad.
    -Estudiar las CMIs de colistina y meropenem en las cepas provenientes de los pacientes. Relacionar estas CMIs iniciales con el pronóstico final (curación clínico-microbiológica y mortalidad).
    -Analizar las interacciones in vitro de los antibióticos utilizados solos y en combinación frente a las cepas aisladas (tests de sinergia).
    -Estudios de la epidemiología molecular y mecanismos de resistencia a los antibióticos y testde sinergia de las cepas bacterianas aisladas.
    -Eventos adversos durante el tratamiento(nefrotoxicidad /neurotoxicidad/diarrea por Clostridium difficile).
    E.5.2.1Timepoint(s) of evaluation of this end point
    At the first 30 days.
    En los 30 primeros días.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the trial will be defined as the last visit of the last patient recruited.
    Se considerará final del ensayo la fecha de la última visita del último sujeto reclutado.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 52
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    ICU Patients
    Pacientes de la UCI
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state152
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will receive adequate treatment by their physician.
    Los pacientes recibirán el tratamiento que su médico considere oportuno.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-07-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-05-06
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 02:40:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA